Physician profile
Nicole E Davis
NPI 1265798979
$1,181.08
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $107 · 2021: $71.16 · 2022: $173 · 2023: $276 · 2024: $291 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $452.55 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $195.06 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $147.76 | 2020-2024 | Jornay Pm |
| Tris Pharma INC | $111.31 | 2020-2023 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $57.19 | 2021-2024 | Qelbree, Qelbree |
| Shire North American Group INC | $44.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.46 | 2020-2023 | |
| Biomarin Pharmaceutical INC. | $25.44 | 2024 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $20.90 | 2024 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $20.49 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $17.86 | 2024 | Myfembree |
| Vertical Pharmaceuticals, LLC | $15.23 | 2025 | Relexxii |
| Abbott Laboratories | $14.33 | 2023 | Id Now Instrument |
| Sanofi Pasteur INC. | $13.48 | 2021 | |
| Pfizer INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.